A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: unfavourable (6), unpleasant (24), poor (225), bad (130), difficult (348), unhelpful (9), opposing (47)

Bevacizumab ver 1

Description
Chemotherapy Protocol CNS CANCER BEVACIZUMAB This protocol may require funding. This is an unlicensed indication for bevacizumab. Regimen CNS-Bevacizumab Indication Recurrent GBM WHO perform
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CNS/Bevacizumab-ver-1.pdf

Atezolizumab-Bevacizumab

Description
Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description
Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indication • Ipilimumab in combination with nivolumab is i
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven his
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after radical chemoradiotherapy • WHO pe
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is indicated where; - the
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Brigatinib

Description
Chemotherapy Protocol Lung Cancer Regimen Brigatinib • NSCLC – Brigatinib Indication • Brigatinib is indicated as monotherapy for the treatment of
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Brigatinib.pdf

Health and safety policy

Description
Health and Safety Policy Date Issued: 21/11/18 Review Date: 21/11/21 Document Type: Policy Version: 10.0 Contents Paragraph 1 2 3 4 5 6 7 8 9 Appendices
Url
/Media/UHS-website-2019/Docs/Policies/Health-and-safety-policy.pdf

Capecitabine-Lapatinib

Description
Chemotherapy Protocol BREAST CANCER CAPECITABINE-LAPATINIB This protocol may require funding Regimen • Breast Cancer – Capecitabine-Lapatinib Indication • Treatment of locally advanced or met
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/CapecitabineLapatinib.pdf

Azacitidine5

Description
Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (5 da
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5.pdf
31 to 40 of 663
Previous … 2 3 4 5 6 … Next